In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alexion will pay $610mm plus earn-outs to buy Enobia

Executive Summary

Public biotech Alexion Pharmaceuticals Inc. is acquiring closely held Enobia Pharma Inc. (developing enzyme replacement therapies for bone and metabolic disorders) for $610mm in cash and up to $470mm in earn-outs based on regulatory and sales goals.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Cash for Equity

Related Companies

UsernamePublicRestriction

Register